相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study
Suzanne Arnold et al.
AMERICAN HEART JOURNAL (2022)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Avivit Cahn et al.
DIABETES CARE (2022)
Association of Baseline HbA(1c) With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Avivit Cahn et al.
DIABETES CARE (2022)
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials
Nitish K. Dhingra et al.
ESC HEART FAILURE (2022)
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials
Nitish K. Dhingra et al.
ESC HEART FAILURE (2021)
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
Muthiah Vaduganathan et al.
DIABETES OBESITY & METABOLISM (2021)
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Tamara K. Young et al.
DIABETOLOGIA (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Duration of Diabetes and Incident Heart Failure The ARIC (Atherosclerosis Risk In Communities) Study
Justin B. Echouffo-Tcheugui et al.
JACC-HEART FAILURE (2021)
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial
Harpreet S. Bajaj et al.
DIABETES OBESITY & METABOLISM (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease
Jelena P. Seferovic et al.
SCIENTIFIC REPORTS (2018)
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
Silvio E. Inzucchi et al.
CIRCULATION (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
Alexander J. M. Brown et al.
BMC CARDIOVASCULAR DISORDERS (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin in the treatment of type 2 diabetes: evidence to date
Jay H. Shubrook et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
Sophia Zoungas et al.
DIABETOLOGIA (2014)
Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population
Kazuo Eguchi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
The significant effect of diabetes duration on coronary heart disease morality - The Framingham Heart Study
CS Fox et al.
DIABETES CARE (2004)